Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

This study is testing a drug called nintedanib — already approved for lung scarring diseases — in people who have developed a serious lung complication called Bronchiolitis Obliterans Syndrome (BOS) after a bone marrow or stem cell transplant. BOS causes the small airways in the lungs to become inflamed and scarred, making it progressively harder to breathe. Researchers want to find out whether nintedanib can slow or stop this decline in lung function. You may be eligible if: - You are 18 or older and received a stem cell transplant within the past 5 years - You have been diagnosed with BOS according to NIH criteria (low FEV1, absence of respiratory infection, and supporting imaging or lung function evidence) - You were diagnosed with BOS within the past 6 months, or your lung function has declined by 10% or more in the past year You may NOT be eligible if: - You have known intolerance to nintedanib - You are pregnant or breastfeeding - You have severely abnormal liver tests (unless caused by GvHD) - You have had a lung infection in the past 4 weeks - You require chronic oxygen therapy or ventilator support - Your blood cancer has relapsed, or you have less than 1 year life expectancy - You are on therapeutic anticoagulation (blood thinners) Talk to your doctor about whether your current medications, liver function, and transplant history make you a good candidate for this trial.